Qiagen (QGEN) Stock Price, News & Analysis

Company Overview

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions. In the diagnostics arena, Qiagen develops and markets molecular tests for infectious diseases, oncology markers and hereditary disorders, supporting both centralized laboratories and point-of-care settings.

Founded in 1984 and headquartered in Hilden, Germany, Qiagen operates in more than 30 countries across the Americas, Europe, the Middle East, Africa and the Asia-Pacific region. Over the years, the company has expanded its global footprint through strategic partnerships, collaborations with academic institutions and targeted acquisitions aimed at enhancing its molecular testing capabilities and broadening its technology platform.

Qiagen is led by Chief Executive Officer Thierry Bernard, under whose stewardship the company continues to invest in research and development, strengthen its supply-chain resilience and pursue digital initiatives to support data-driven insights. With a strong focus on innovation and quality, Qiagen serves a diverse customer base, including clinical laboratories, biopharmaceutical companies and life-science researchers worldwide.

Key Stats

• Today's Range: $41.16 to $41.64
• 50-Day Range: $33.78 to $42.00
• 52-Week Range: $32.53 to $57.81
• Volume: 1.84 million shs
• Average Volume: 3.02 million shs
• Market Capitalization: $8.53 billion
• P/E Ratio: 21.61
• Dividend Yield: 0.85%
• Price Target: $43.34
• Consensus Rating: Hold

Qiagen Stock Analysis - MarketRank™

Qiagen scored higher than 79% of companies evaluated by MarketBeat, and ranked 126th out of 836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Hold

Consensus Rating

Qiagen has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 1 strong buy rating, 4 buy ratings, 8 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Qiagen is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Qiagen has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 7.82%

Earnings Growth

Earnings for Qiagen are expected to grow by 7.82% in the coming year, from $2.43 to $2.62 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Qiagen is 21.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.04.

Price to Earnings Ratio vs. Sector

The P/E ratio of Qiagen is 21.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.11.

Price to Earnings Growth Ratio

Qiagen has a PEG Ratio of 4.14. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Qiagen has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.23% of the float of Qiagen has been sold short.

Short Interest Ratio / Days to Cover

Qiagen has a short interest ratio ("days to cover") of 2.08, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Qiagen has recently increased by 19.96%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Qiagen has a dividend yield of 0.86%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Qiagen does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Qiagen is 18.32%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Qiagen will have a dividend payout ratio of 13.36% next year. This indicates that Qiagen will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 1.75

News Sentiment

Qiagen has a news sentiment score of 1.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Qiagen this week, compared to 5 articles on an average week.

Search Interest

5 people have searched for QGEN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Qiagen insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.00% of the stock of Qiagen is held by insiders.

Percentage Held by Institutions

70.00% of the stock of Qiagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Record date for 7/14 Dividend: 7/07/2026
• Ex-Dividend for 7/14 Dividend: 7/07/2026
• Dividend Payable: 7/14/2026
• Today: 7/25/2026
• Next Earnings (Confirmed): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:QGEN
• CIK: 1015820
• Web: www.qiagen.com
• Phone: (177) 355-6600
• Fax: 31-77-355-6658
• Employees: 5,654
• Year Founded: 1984

Price Target and Rating

• Average Price Target for Qiagen: $43.34
• High Price Target: $59.00
• Low Price Target: $36.00
• Potential Upside/Downside: +4.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.36
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.91
• Trailing P/E Ratio: 21.61
• Forward P/E Ratio: 17.03
• P/E Growth: 4.14
• Net Income: $424.88 million
• Net Margins: 19.16%
• Pretax Margin: 21.75%
• Return on Equity: 14.40%
• Return on Assets: 8.40%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 3.21
• Quick Ratio: 2.57

Sales & Book Value

• Annual Sales: $2.10 billion
• Price / Sales: 4.06
• Cash Flow: $3.40 per share
• Price / Cash Flow: 12.17
• Book Value: $17.89 per share
• Price / Book: 2.31

Miscellaneous

• Outstanding Shares: 206,075,000
• Free Float: 187,528,000
• Market Cap: $8.53 billion
• Optionable: Optionable
• Beta: 0.64